# HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection

> **NCT05311319** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 70 (estimated)

## Conditions studied

- Hepatocarcinoma

## Interventions

- **DRUG:** HAIC+TQB2450+Anlotinib

## Key facts

- **NCT ID:** NCT05311319
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-11
- **Primary completion:** 2022-12
- **Final completion:** 2023-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2022-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05311319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05311319, "HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05311319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*